The Leon Berard Clinical Center (CLB) is an integrated cancer research center relying on the excellence of the basic research conducted at the Cancer Research Center in Lyon (CRCL), a high quality translational research labeled by the SIRIC program of INCa (LYric) and an efficient clinical research labelled ISO 9001 since July 2013. The translational research department gathers technological platforms, such as the biological resource center - certified NFS 96 900, a pathology department dedicated to research, the cancer genomics platform, the immunomonitoring platform and the ex-vivo platform, which all contribute to accelerate the transfer of innovations of its research programs to the clinic.
The CLB is one of the founders, along with Claude Bernard University, INSERM and the Hospices Civils de Lyon, of the scientific cooperation foundation created in 2007, Synergie Lyon Cancer (SLC). Through its missions, the SLC Foundation supports research activity carried out in Lyon in the field of tumor escape and therapeutic targeting. It is composed of three technological platforms: 1) the laboratory of experimental models (LMT) dedicated to establish panels of relevant tumor models in oncology; 2) the bioinformatics platform Gilles Thomas with recognized expertise in Whole Genome Sequencing; 3) the Drug Discovery and Development Center, which promotes the development of molecules derived from the basic research of the Leon Berard Clinical Center or the CRCL.
The CLB, with its clinical and technological expertise, and the SLC Foundation via the LMT and the Bioinformatics platform, play a central role in the IMODI project. They participate in the generation and the characterization of PDX models of breast and ovarian tumors in order to make them available to the medical and scientific community. Furthermore, thanks to the expertise of two researchers from the CRCL, Dr Bertrand Dubois and Dr Fabrice Lavial, an innovative approach to humanize the immune system of mice has been developed in order to mimic the interactions of the tumor with its microenvironment.
As of today, nearly 40 models of breast cancers, similar to the patients’ tumors, are on track to be finalized. Dr Séverine Tabone-Eglinger, PharmD-PhD, coordinator of the IMODI project at the CLB and the SLC Foundation, will present this PDX collection at the AACR's annual meeting on April 4th, 2017.